DB04879InvestigationalSmall molecule
Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
- Mechanism
- Curator reviewed
Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
- Primary indication
- Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).Curator reviewed
- Formula / weight
- C20H15ClN4 · 346.813 g/mol (avg)
- Also known as
- Vatalinib
- Code names
- BAY-86-5127 · CGP-79787 · CGP-797870 · K-222584 · NVP-PTK787 · PTK 787 · PTK787/ZK 222584 · PTK/ZK · ZK-232934
Resolves to
Clinical / RWD
Structure
InChIKey
YCOYDOIWSSHVCK-UHFFFAOYSA-NSMILESClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C3=CC=CC=C23)C=C1What you can answer from here — as of October 01, 2026
Which drugs share a target with Vatalanib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account